Evaluating the Safety and Efficacy of SGLT-2 Inhibitors on Reducing Cardiovascular and Renal Mortality, Morbidity and Inflammatory Outcomes in Various Patient Populations: A Systematic Review and Meta-Analysis of 92 920 Patients.

IF 2.3 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS
Clinical Medicine Insights. Cardiology Pub Date : 2025-06-30 eCollection Date: 2025-01-01 DOI:10.1177/11795468251347777
Syed Hamza Haider, Areeka Irfan, Samir Mustafa Sheikh, Muhammad Omar Larik, Alishba Raza, Yumna Khabir
{"title":"Evaluating the Safety and Efficacy of SGLT-2 Inhibitors on Reducing Cardiovascular and Renal Mortality, Morbidity and Inflammatory Outcomes in Various Patient Populations: A Systematic Review and Meta-Analysis of 92 920 Patients.","authors":"Syed Hamza Haider, Areeka Irfan, Samir Mustafa Sheikh, Muhammad Omar Larik, Alishba Raza, Yumna Khabir","doi":"10.1177/11795468251347777","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The effect of Sodium Glucose Co-Transporter 2 inhibitors on cardiovascular, renal, dyslipidemia, and inflammatory markers has not been analyzed simultaneously. The goal is to determine if SGLT2 inhibitors significantly reduce cardiovascular and renal mortality, and improve these health outcomes.</p><p><strong>Methods: </strong>PubMed, Cochrane Library and MEDLINE databases were used to conduct a comprehensive literature search from inception to September 2023. Randomized control trials with follow-up for at least 8 weeks, with a group taking SGLT2 inhibitors being compared with a group taking either placebo or other medication, in which cardiovascular outcomes, renal outcomes, lipid biomarkers, and inflammatory markers were reported as the primary outcomes were included. The statistical analyses were conducted using Review Manager with a random-effects model.</p><p><strong>Results: </strong>Thirteen studies comprising 92 920 patients were analyzed for several outcomes. The analysis revealed a significant reduction in overall mortality, death due to heart failure, cardiovascular causes, and renal causes in the SGLT2 inhibitor group as compared to placebo. Pooled results also revealed a significant reduction in the frequency of renal replacement therapy and renal composite endpoint in patients on SGLT2 inhibitors. There was also a significant reduction in IL-6, TNF-a, systolic blood pressure in the same group. On the other hand, Flow Mediated Dilation (FMD), lipid profile, and the incidence of amputations and fractures showed no significant associated SGLT2 inhibitor therapy.</p><p><strong>Conclusion: </strong>Our analysis indicates that diabetics and non-diabetics suffering from cardiovascular and renal diseases experience a significant reduction in morbidity and mortality from SGLT2 inhibitor therapy, leading to a better prognosis of such conditions in the long-term.</p>","PeriodicalId":10419,"journal":{"name":"Clinical Medicine Insights. Cardiology","volume":"19 ","pages":"11795468251347777"},"PeriodicalIF":2.3000,"publicationDate":"2025-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12214313/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Medicine Insights. Cardiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/11795468251347777","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The effect of Sodium Glucose Co-Transporter 2 inhibitors on cardiovascular, renal, dyslipidemia, and inflammatory markers has not been analyzed simultaneously. The goal is to determine if SGLT2 inhibitors significantly reduce cardiovascular and renal mortality, and improve these health outcomes.

Methods: PubMed, Cochrane Library and MEDLINE databases were used to conduct a comprehensive literature search from inception to September 2023. Randomized control trials with follow-up for at least 8 weeks, with a group taking SGLT2 inhibitors being compared with a group taking either placebo or other medication, in which cardiovascular outcomes, renal outcomes, lipid biomarkers, and inflammatory markers were reported as the primary outcomes were included. The statistical analyses were conducted using Review Manager with a random-effects model.

Results: Thirteen studies comprising 92 920 patients were analyzed for several outcomes. The analysis revealed a significant reduction in overall mortality, death due to heart failure, cardiovascular causes, and renal causes in the SGLT2 inhibitor group as compared to placebo. Pooled results also revealed a significant reduction in the frequency of renal replacement therapy and renal composite endpoint in patients on SGLT2 inhibitors. There was also a significant reduction in IL-6, TNF-a, systolic blood pressure in the same group. On the other hand, Flow Mediated Dilation (FMD), lipid profile, and the incidence of amputations and fractures showed no significant associated SGLT2 inhibitor therapy.

Conclusion: Our analysis indicates that diabetics and non-diabetics suffering from cardiovascular and renal diseases experience a significant reduction in morbidity and mortality from SGLT2 inhibitor therapy, leading to a better prognosis of such conditions in the long-term.

评估SGLT-2抑制剂在降低不同患者人群心血管和肾脏死亡率、发病率和炎症结局方面的安全性和有效性:一项92 920例患者的系统评价和荟萃分析。
背景:葡萄糖共转运蛋白2抑制剂钠对心血管、肾脏、血脂异常和炎症标志物的影响尚未被同时分析。目的是确定SGLT2抑制剂是否能显著降低心血管和肾脏死亡率,并改善这些健康结果。方法:采用PubMed、Cochrane Library和MEDLINE数据库,从建库至2023年9月进行综合文献检索。随机对照试验,随访至少8周,将服用SGLT2抑制剂的组与服用安慰剂或其他药物的组进行比较,其中心血管结局、肾脏结局、脂质生物标志物和炎症标志物作为主要结局报告。采用随机效应模型Review Manager进行统计分析。结果:13项研究包括92 920例患者,分析了几个结果。分析显示,与安慰剂相比,SGLT2抑制剂组的总死亡率、因心力衰竭、心血管原因和肾脏原因导致的死亡显著降低。综合结果还显示,在接受SGLT2抑制剂治疗的患者中,肾脏替代治疗的频率和肾脏复合终点显著降低。在同一组中,IL-6、TNF-a、收缩压也显著降低。另一方面,血流介导的舒张(FMD)、血脂和截肢和骨折的发生率没有显示SGLT2抑制剂治疗的显著相关性。结论:我们的分析表明,患有心血管和肾脏疾病的糖尿病患者和非糖尿病患者在SGLT2抑制剂治疗后的发病率和死亡率显著降低,导致这些疾病的长期预后更好。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Clinical Medicine Insights. Cardiology
Clinical Medicine Insights. Cardiology CARDIAC & CARDIOVASCULAR SYSTEMS-
CiteScore
5.20
自引率
3.30%
发文量
16
审稿时长
8 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信